People profiles
Andreas Kirberg
Professional Background
- Almost 25 years of professional experience
- Andreas worked as a consultant for some major clients like Siemens, BMW and Sun Microsystems
- He also worked as a manager for different large pharmaceutical corporations (ratiopharm and STADA Arzneimittel AG) where he participated in large integration and global M&A projects including carve-outs
- Andreas is a Key Player in an award-winning cross-company initiative designing and realizing an innovative training for knowledge transfer within post-merger integrations as well as M&A
- He speaks fluent German and English
M&A Skills & Expertise
- Andreas has senior executive experience with an extensive international track record in general management, business development, merger & acquisition, integration-, risk-, portfolio- and project management, as well as innovation and patent affairs within the health care and pharmaceutical market
- His experience spectrum covers executive board membership and close collaboration with supervisory board as well as other members of C-level management
- Andreas was the manager in charge of the post-merger integration of Teva/ratiopharm Germany in close contact with the European headquarter
- Andreas developed a wide international and multi-cultural experience working in several countries including America, Europe, Middle East and Asia
Project Highlights
- Teva/ratiopharm, leading the Germany integration of the €3.6bn acquisition of ratiopharm including prior carve-out of Suisse operations with Sales of €150m
- Integrated brand product portfolio acquired from Grünenthal into STADA’s R&D organization in the Middle & Eastern Europe, Russia and the Middle East (transaction volume € 312m)
- Acquisition and integration of Thornton+ Ross a British OTC company (transaction volume € 260m) with Sales in over 60 countries
- Acquisition and integration of Sciotec, an Austrian OTC company (transaction volume €17.2m)
- Planned and executed strategic initiative Expansion Latin America; performed market potential analysis identified main markets and conducted two due diligences in Brazil and Columbia
- Acquisition and integration of Argentinian generics producer Laboratorio Vannier S.A. (transaction volume €12m)